Evaluation of Immunogenicity and Safety of GSK Biologicals' Tdap Booster Vaccine (Boostrix™) in Young Adults, Administered 10 Years After Previous Tdap Boosting
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Tetanus
- Sponsor
- GlaxoSmithKline
- Enrollment
- 165
- Locations
- 1
- Primary Endpoint
- Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T).
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
The purpose of this follow-up study is to evaluate the persistence of antibodies against all the vaccine antigens 10 years after booster vaccination with either Tdap or Td, and also to assess immunogenicity and safety of another dose of Boostrix, administered in this study. This protocol posting deals with objectives and outcome measures of the extension phase. The objectives and outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00109330).
Detailed Description
Subjects were previously vaccinated with either Boostrix or a control Td vaccine in study NCT00109330. Only subjects who were part of the primary study will be invited to participate in this study. All subjects will receive a single dose of Boostrix at Visit 1 (Day 0) and subjects will be observed till Visit 2 (Day 30) for safety in terms of solicited adverse events (during 4 days post vaccination), unsolicited adverse events (during 31 days post vaccination) and serious adverse event (during the trial period). A blood sample will be collected from all subjects before vaccination (Visit 1) and one month after vaccination (Visit 2) for antibodies estimation. This summary has been updated following Protocol amendment 2 dated 03 October 2013. The protocol is being amended to facilitate enrolment by: * - Extending the window period for re-vaccination from ± 6 months to ± 300 days from the Year 10 time point. * - Extending the recruitment period from 6 months to 14 months. The format of non-inferiority criterion of the first co-primary objective has been updated to keep it aligned with the format of non-inferiority criterion of the second co-primary objective.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visit).
- •Subjects who have received a dose of Tdap or Td vaccines 10 years (+/-300 days) back, in study NCT
- •Written informed consent obtained from the subject.
- •Healthy subjects as established by medical history and clinical examination before entering into the study.
- •Female subjects of non-childbearing potential may be enrolled in the study.
- •Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.
- •Female subjects of childbearing potential may be enrolled in the study, if the subject
- •has practiced adequate contraception for 30 days prior to vaccination, and
- •has a negative pregnancy test on the day of vaccination, and
- •has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the vaccine dose.
Exclusion Criteria
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the dose of study vaccine, or planned use during the study period.
- •Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccine dose . For corticosteroids, this will mean prednisone (≥ 20 mg/day (for adult subjects), or equivalent. Inhaled and topical steroids are allowed.
- •Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 31 days after the dose of vaccine, with the exception of Influenza vaccine which is allowed throughout the study period.
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device).
- •Previous vaccination against diphtheria, tetanus or pertussis since the last dose received in the Study NCT
- •History of diphtheria, tetanus or pertussis diseases following the receipt of booster dose in the Study NCT
- •Severe allergic reaction (e.g. anaphylaxis) after previous administration of any tetanus toxoid, diphtheria toxoid, or pertussis-antigen containing vaccines, or any component of Boostrix.
- •Hypersensitivity to latex.
- •Encephalopathy (e.g. coma, decreased level of consciousness, prolonged seizures) of unknown etiology occurring within 7 days following previous vaccination with pertussis-containing vaccine.
- •History of any neurological disorders or seizures.
Outcomes
Primary Outcomes
Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T).
Time Frame: At Month 1
A seroprotected subject was defined as a subject with anti-D/anti-T antibody concentrations above or equal (≥) to 0.1 IU/mL (international units per milliliter)
Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Against Filamentous Hemagglutinin (Anti-FHA) and Against Pertactin (Anti-PRN).
Time Frame: At Month 1
Concentrations were expressed in geometric mean concentrations (GMCs).
Secondary Outcomes
- Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Against Filamentous Hemagglutinin (Anti-FHA) and Against Pertactin (Anti-PRN).(At Month 0)
- Number of Subjects With a Booster Response to Anti-D and Anti-T.(At Month 1)
- Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T).(At Month 0)
- Anti-D and Anti-T Antibody Concentrations.(At Month 0 and Month 1)
- Number of Subjects With Serious Adverse Events (SAEs).(From Day 0 to 31 days post-vaccination.)
- Number of Subjects With a Booster Response to Anti-PT, Anti-FHA and Anti-PRN.(At Month 1.)
- Number of Subjects With Unsolicited Adverse Events (AEs).(During the 31 days (Day 0 - 30) after vaccination.)
- Number of Subjects With Anti-D and Anti-T Concentrations Above the Cut-off.(At Month 0 and Month 1)
- Number of Subjects With Solicited Local Symptoms.(During the 4 days (Day 0 - 3) follow-up period after vaccination.)
- Number of Subjects With Solicited General Symptoms.(During the 4 days (Day 0 - 3) follow-up period after vaccination.)